Frankenburg F R, Tohen M, Cohen B M, Lipinski J F
Laboratories for Psychiatric Research, McLean Hospital, Belmont, Massachusetts 02178.
J Clin Psychopharmacol. 1988 Apr;8(2):130-2.
Carbamazepine is now used by many clinicians in the treatment of bipolar disorder (BD) refractory to standard treatments, including lithium and neuroleptics. Little information is yet available about the utility and efficacy of this novel treatment during long-term use. We carried out a retrospective study of 50 patients (34 with BD) who had received carbamazepine for the treatment of a psychotic disorder. Two-thirds (22) of the BD patients and two of the 16 patients with other diagnoses appeared to respond to carbamazepine acutely. However, follow-up 3 to 4 years later revealed that only eight patients (seven with BD) were still receiving the drug. In only two cases was the treating psychiatrist convinced that carbamazepine was clearly beneficial. Side effects, particularly hematological abnormalities, during both short- and long-term treatment were troublesome. Carbamazepine may only infrequently be useful in the long-term care of patients who fail to respond to standard treatment.
目前,许多临床医生使用卡马西平治疗对包括锂盐和抗精神病药物在内的标准治疗无效的双相情感障碍(BD)。关于这种新疗法长期使用的效用和疗效,目前尚无太多信息。我们对50例接受卡马西平治疗精神障碍的患者(34例双相情感障碍患者)进行了一项回顾性研究。三分之二(22例)的双相情感障碍患者和16例其他诊断患者中的2例似乎对卡马西平有急性反应。然而,3至4年后的随访显示,只有8例患者(7例双相情感障碍患者)仍在服用该药。只有2例病例中,主治精神科医生确信卡马西平明显有益。短期和长期治疗期间的副作用,尤其是血液学异常,令人困扰。卡马西平在对标准治疗无反应的患者的长期护理中可能很少有用。